William Fairey
CIK 1727275 · EVP, Chief Commercial Officer · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$248.4K
Companies
6
Total Filings
24
Lifetime Open-Market Net
-$352.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIRM | Director | 2,500 | $99.38 | $248.4K | -$155.1K | 7 | 2026-06-17 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | — | $27.00 | — | $0 | 4 | 2026-06-11 |
| RNTX | Director | — | $0.80 | — | $0 | 1 | 2025-07-23 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 3 | 2024-12-06 |
| MyoKardia, Inc. (MYOK) Delisted | See Remarks | 8,125 | — | — | -$197.2K | 3 | 2020-02-19 |
| CCXI | Chief Operating Officer | — | $16.67 | — | $0 | 1 | 2018-01-05 |
Recent Filings · Page 2 of 3
24 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-04 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-22 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2024-04-22 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-05 | ASND | Notice (144) | −200 | -$29.6K | EDGAR |
| 2023-11-02 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-14 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2021-08-20 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2020-11-19 | — | Mixed | −42,199 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.